“In this study of sperm parameters before and after 2 doses of a COVID-19 mRNA vaccine, there were no significant decreases in any sperm parameter among this small cohort of healthy men. Because the vaccines contain mRNA and not the live virus, it is unlikely that the vaccine would affect sperm parameters. While these results showed statistically significant increases in all sperm parameters, the magnitude of change is within normal individual variation and may be influenced by regression to the mean.5 Additionally, the increase may be due to the increased abstinence time before the second sample. Men with oligospermia [low sperm count] did not experience further decline.”
(J. Harris: Thank goodness the family jewels are safe — and in good working order?)
The COVID-19 vaccine will now be available Monday through Friday at designated Christus Trinity Clinic primary care locations in Longview, Marshall and Kilgore. Walk-in appointments also are available at Christus Trinity Clinic Urgent Care, 2021 W. Loop 281 in Longview….
All patients will receive the Pfizer vaccine, which is available to everyone 12 and older. The vaccine remains free to patients. Those interested in receiving a vaccine may schedule an appointment online at vaccinate.christushealth.org.
(J. Harris: Thank you Christus Hospitals in Longview, Tyler, and Marshall for your tireless vaccination work. THANK YOU AGAIN! We also want to thank Texas Eastman for their financial donation and support as well.)
“….As of today, close to 33 million people in the US have been diagnosed with COVID-19. Some reports have suggested that up to 80% of these patients, even many who were asymptomatic, can have demonstrable lung injury. It remains to be seen whether or not other patients who have recovered from mild, moderate, or even severe COVID-19 are going to be organ donors. If not, this may lead to a significant contraction of our donor pool.’
(J. Harris: A moving interview with a transplant surgeon.)
1. Inside Pfizer’s Race to Produce the World’s Biggest Supply of Covid Vaccine (Washington Post) The first attempt to produce industrial-scale quantities of the experimental vaccine that has played a central role in arresting the coronavirus pandemic in the United States was a total failure. Operators at a Pfizer plant outside Kalamazoo hoped the trial run could provide quick validation of the company’s gamble on a newfangled mRNA technology. It also was an early test of Pfizer’s strategy of refusing government aid to develop and rapidly ramp up commercial scale production of its vaccine.
2. Hope Amid Challenging Times for Antibiotic Developers (CIDRAP) A new report from the Access to Medicine Foundation (AMF) is highlighting innovative approaches that these small- and medium-sized enterprises, or SMEs, are using to navigate this challenging environment. These approaches could help ensure that powerful new antibiotics not only come to
market, but are used judiciously and are available to the populations that need them the most.
3. Has a ‘Moscow Strain’ of Coronavirus Emerged? (Moscow Times) The developers of Russia’s Sputnik V coronavirus vaccine are studying the jab’s effectiveness against the so-called “Moscow strain” of the virus, they told the state-run RIA Novosti news agency Tuesday. Gamaleya Center head Alexander Gintsburg’s comments come as Moscow officials have sounded the alarm over the Russian capital’s surge in new infections, with reported daily cases more than doubling in the past week.
4. How the COVID pandemic Is Changing Global Science Collaborations (Nature) Early in the COVID-19 pandemic, science leaders talked widely about leveraging global knowledge and working together. Researchers have paid particular attention to collaboration between the United States and China, the two nations with the biggest scientific output. In the first few months of the pandemic, these two countries collaborated on COVID-19 papers more than any other pair of nations, and at higher rates than they did for non-COVID-19 science. But as the pandemic wore on, the United States turned instead to collaborating on COVID-19 papers with other countries, such as the United Kingdom.. This corresponded with a decline in China’s relative contribution to the literature, as case rates went down and as the government restricted the flow of information about COVID-19.
5. CureVac’s Covid-19 Vaccine Disappoints in Clinical Trial (New York Times) The trial, which included 40,000 volunteers in Latin America and Europe, estimated that CureVac’s mRNA vaccine had an efficacy of just 47 percent, among the lowest reported so far from any Covid-19 vaccine maker. The trial will continue as researchers monitor volunteers for new cases of Covid-19, with a final analysis expected in two to three weeks.
AND LAST BUT NOT LEASED:
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.